Carboplatin is a chemotherapy drug used against some forms of cancer. It was introduced in the late 1980s and has since gained popularity in clinical treatment due to its vastly reduced side-effects compared to its parent compound cisplatin. Cisplatin and carboplatin, as well as oxaliplatin, are classified as DNA alkylating agents.
History
Bristol-Myers Squibb gained
Food and Drug Administration (FDA) approval for carboplatin, under the brand name Paraplatin, in March 1989. The drug went generic in October 2004. There are also generic versions of the drug available from APP, Bedford, Sicor, Mayne Pharma, Pharmachemie, Pliva, Sandoz, Spectrum.
Pharmacology
Chemistry
Carboplatin differs from cisplatin in that it has a closed cyclobutane dicarboxylate (CBDCA) moiety on its leaving arm in contrast to the readily leaving chloro groups. This results in very different DNA binding kinetics, though it forms the same reaction products in vitro at equivalent doses with cisplatin. However, recent studies provide a new caveat on the DNA binding molecular mechanisms with the possibility of being activated by nucleophiles (as opposed to cisplatin), before forming the toxic adducts. There are also results to show that cisplatin and carboplatin cause different morphological changes in MCF-7 cell lines while exerting their cytotoxic behaviour.
More on
[ Carboplatin ]
MedlinePlus: Carboplatin - Provides information on usage, precautions, side effects and brand names when available. Data provided by government agencies and health-related organizations.
Meta Description: [ Carboplatin ]